Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
Hatim Lokhandwala, Clinical Research Coordinator, Hope & Healing Cancer Services LLC, shared a post on LinkedIn:
“Landmark HI-PRO Trial Redefines VTE Treatment Guidelines: Extended Apixaban Significantly Reduces Recurrence Risk in High-Risk Patients
The recently published HI-PRO trial in the New England Journal of Medicine provides critical, evidence-based direction for the challenging clinical scenario of managing Venous Thromboembolism (VTE) in patients with a history of a transient provoking factor but also concomitant enduring risk factors (e.g., obesity, chronic lung disease, autoimmune disorders).
The study, which investigated the use of extended-duration, low-intensity apixaban (2.5 mg twice daily) versus placebo for 12 months, strongly suggests that a simple “provoked vs. unprovoked” paradigm is insufficient for determining anticoagulation duration.
Here are the pivotal findings for the clinical community:
- Significant Efficacy: Low-intensity apixaban resulted in a substantially lower rate of symptomatic recurrent VTE (the primary efficacy outcome) compared to placebo.
- The recurrence rate was 1.3% in the apixaban group versus 10.0% in the placebo group (Hazard Ratio, 0.13; 95% CI, 0.04 to 0.36; P<0.001).
- Favorable Safety Profile: The use of low-intensity apixaban maintained a low risk of the primary safety outcome, major bleeding.
- Only 1 patient (0.3%) in the apixaban group experienced major bleeding, compared to none in the placebo group (P>0.999).
- Clinical Implications: The 10% recurrence risk observed in the placebo group demonstrates that the presence of enduring risk factors places these “provoked” VTE patients at a high risk for recurrence, approximating that of traditional high-risk (unprovoked) VTE patients.
This data strongly supports a move toward personalized risk stratification for VTE, demonstrating that extending anticoagulation with a low-dose Factor Xa inhibitor provides a robust net clinical benefit for a previously ambiguous patient population.”
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber
Read full article here.
Stay updated with Hemostasis Today.
-
Oct 11, 2025, 09:06Natalia Peres Martinez - Surgical Bleed: Replacing Gut Feeling With Guided Thinking
-
Oct 11, 2025, 09:00Muhammad Ali - Hematology In Pakistan: The Silent Revolution In Diagnosis And A Blueprint For Growth
-
Oct 11, 2025, 08:50Robert Zeiser: New Insights and Timeless Lessons in Transplantation
-
Oct 11, 2025, 08:39Mildred Lundgren: These 5 Proposals Are A Clear Road Map for The Future And We Support Them Wholeheartedly
-
Oct 11, 2025, 08:33RPTH Journal: Does Fasting Affect Anticoagulant Therapy? - The Effects Of Fasting During Ramadan
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 11, 2025, 18:47Endovascular Today: SYMPHONY-PE Trial and Advances in Pulmonary Embolism Treatment
-
Oct 11, 2025, 08:49Rodrigo Assar: We Are Pushing the Boundaries by Using Computational Approaches
-
Oct 11, 2025, 08:48Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
-
Oct 11, 2025, 08:34Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 11, 2025, 08:57Jeff June - Seeing The Invisible: How Spatial Biology Is Opening A New Chapter In Stroke Care
-
Oct 11, 2025, 08:11Khaled Musallam: Honored to Be Featured for The 7th Year in A Row in The World’s Top 2% Most-Cited Scientists
-
Oct 11, 2025, 08:07Britta Diebel: This Has Been An Intense, Good Week, Although IPAW Actually Lasts All Year Long
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?